Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(33.3%)

N/A

2(33.3%)

Phase 2

2(33.3%)

6Total

Phase 4(2)

N/A(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07632170Not ApplicableNot Yet Recruiting

The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations

Role: lead

NCT07190261Phase 2Not Yet Recruiting

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Role: lead

NCT05399732Phase 2Completed

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

Role: lead

NCT06847607Not ApplicableNot Yet Recruiting

A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

Role: lead

NCT04470804Phase 4Completed

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

Role: lead

NCT03364764Phase 4Completed

Sirolimus Treatment for Refractory PRCA

Role: lead

All 6 trials loaded